Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Sabatino, Maria A ^a   Marabese, Mirko ^a   Ganzinelli, Monica ^a   Caiola, Elisa ^a   Geroni, Cristina ^b   Broggini, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3'',4' ANHYDRO(2'' METHOXY 3'' HYDROXY 4'' MORPHOLINYL)DOXORUBICIN; DOXORUBICIN DERIVATIVE; NEMORUBICIN; NUCLEIC ACID BINDING PROTEIN; PNU 159682; PROTEIN XPG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC 5; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; EPIGENETICS; EXCISION REPAIR; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OVARY TUMOR; PHARMACOGENETICS; PROMOTER REGION; ANIMAL; CHO CELL; CRICETULUS; DNA METHYLATION; DNA REPAIR; DRUG RESISTANCE; GENETICS; HAMSTER; METABOLISM; NEOPLASM; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DNA METHYLATION; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 77956893417     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-259     Document Type: Article

References (35)

1. Damia G, D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007, 43(12):1791-1801. 10.1016/j.ejca.2007.05.003, 17588740.
2. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, et al. Inherited susceptibility to lung cancer may be associated with the T790 M drug resistance mutation in EGFR. Nat Genet 2005, 37(12):1315-1316. 10.1038/ng1671, 16258541.
3. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275-284. 10.1038/nrc1590, 15803154.
4. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007, 67(15):2257-2276. 10.2165/00003495-200767150-00009, 17927287.
5. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007, 8(7):595-602. 10.1016/S1470-2045(07)70175-4, 17586092.
6. Huygh G, Clement PM, Dumez H, Schoffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006, 2006:56282. 10.1155/SRCM/2006/56282, 1820623, 17496996.
7. von Mehren M. Trabectedin--a targeted chemotherapy?. Lancet Oncol 2007, 8(7):565-567. 10.1016/S1470-2045(07)70181-X, 17613417.
8. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001, 92(4):583-588. 10.1002/ijc.1221, 11304695.
9. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001, 7(8):961-966. 10.1038/91008, 11479630.
10. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996, 56(21):4881-4886.
11. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998, 58(16):3579-3585.
12. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2007, 6(8):1079-1099. 10.1016/j.dnarep.2007.03.008, 17485253.
13. Klapacz J, Meira LB, Luchetti DG, Calvo JA, Bronson RT, Edelmann W, Samson LD. O6-methylguanine-induced cell death involves exonuclease 1 as well as DNA mismatch recognition in vivo. Proceedings of the National Academy of Sciences 2009, 106(2):576-581.
14. Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Muller M, Groen HJ, Smit EF, de Vries EG. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 1997, 73(3):362-366. 10.1002/(SICI)1097-0215(19971104)73:3<362::AID-IJC10>3.0.CO;2-F, 9359483.
15. Mariani M, Capolongo L, Suarato A, Bargiotti A, Mongelli N, Grandi M, Beck WT. Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR. Invest New Drugs 1994, 12(2):93-97. 10.1007/BF00874437, 7860237.
16. Ripamonti M, Capolongo L, Melegaro G, Gornati C, Bargiotti A, Caruso M, Grandi M, Suarato A. Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives. Invest New Drugs 1996, 14(2):139-146. 10.1007/BF00210784, 8913834.
17. Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M, Zanovello P. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Res 2000, 60(12):3232-3238.
18. Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, Zanovello P, Floreani M. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 2005, 11(4):1608-1617. 10.1158/1078-0432.CCR-04-1845, 15746066.
19. Geroni C, Pesenti E, Broggini M, Belvedere G, Tagliabue G, D'Incalci M, Pennella G, Grandi M. L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. Br J Cancer 1994, 69(2):315-319. 1968686, 8297727.
20. Vilpo JA, Vilpo LM, Szymkowski DE, O'Donovan A, Wood RD. An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Mol Cell Biol 1995, 15(1):290-297. 231955, 7799936.
21. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 28; 451(7182):1111-5.
22. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4(4):296-307. 10.1038/nrc1319, 15057289.
23. Saffi J, Agnoletto MH, Guecheva TN, Batista LFZ, Carvalho H, Henriques JAP, Stary A, Menck CFM, Sarasin A. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells. DNA Repair 2010, 9(1):40-47. 10.1016/j.dnarep.2009.10.003, 19926538.
24. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996, 66(6):779-783. 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z, 8647649.
25. Beumer JH, Buckle T, Ouwehand M, Franke NE, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest New Drugs 2007, 25(1):1-7. 10.1007/s10637-006-7773-9, 16633714.
26. Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, Vignati S, Faircloth G, Jimeno J, D'Incalci M. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 2000, 82(10):1732-1739. 10.1054/bjoc.2000.1224, 2374505, 10817511.
27. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007, 25(29):4603-4609. 10.1200/JCO.2007.10.8688, 17925555.
28. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6(2):107-116. 10.1038/nrc1799, 16491070.
29. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005, 45:629-656. 10.1146/annurev.pharmtox.45.120403.095832, 15822191.
30. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128(4):683-692. 10.1016/j.cell.2007.01.029, 17320506.
31. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004, 10(13):4420-4426. 10.1158/1078-0432.CCR-03-0732, 15240532.
32. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998, 95(15):8698-8702. 10.1073/pnas.95.15.8698, 21139, 9671741.
33. Izzo AMCF, Vogl TJ, Middleton M, Valle JW, Fiore F, Gadaleta CD, Pirotta RM, Martignoni M, Laffranchi B. Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results. J Clin Oncol 2009, 25(15s).
34. Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto T, et al. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 2009, 10(1):47-52. 10.3816/CLC.2009.n.007, 19289372.
35. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol 2008, 26(18):2952-2958. 10.1200/JCO.2007.13.5806, 18565881.